Progress of chemotherapy and combined therapy in patients with gastric cancer
Wang Qilu (Cancer Institute & Hospital CAMS & PUMC, Beijing 100021, China)
Gastric cancer is a common malignant tumor. It is a leading cause of cancer death in China. Most patients are difficult to be discovered early because of lacking specific signs. Chemotherapy has moderate efficacy for gastric cancer, therefore, surgery plus adjuvant chemotherapy has became a majority procedure role. We reviewed domestic and foreign literatures and systematically introduced the response and evaluation of gastric cancer chemotherapy, particularly drugs dosage, response, indications and overall survival rates. Chemotherapy or combination therapy can be used in the late stage patients or in the preoperation and/or postoperation patients. In the preoperation periods chemotherapy can be helpful to improve radical resection. In the postoperation cases, it can reduce the cancer relapse or metastasis. In order to prevent the peritoneal recurrence, intra-peritoneal chemotherapy can be used in the postoperation cases. In summary, chemotherapy or combined therapy can reduce recurrence in the gastric cancer and improve patients survival.